Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.

Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK; Pediatric AIDS Clinical Trials Group P1005 Study Team..

Pediatr Infect Dis J. 2004 Aug;23(8):713-8.

PMID:
15295220
2.

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.

Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A; T20-310 Study Group..

Pediatr Infect Dis J. 2007 Sep;26(9):799-805.

PMID:
17721374
3.

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children.

Church JA, Cunningham C, Hughes M, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Purdue L, Hawkins E, Sista P; PACTG P1005 Study Team. Pediatric AIDS Clinical Trials Group..

Pediatr Infect Dis J. 2002 Jul;21(7):653-9.

PMID:
12237598
4.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group..

N Engl J Med. 2003 May 29;348(22):2186-95.

5.

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J.

Antivir Ther. 2003 Aug;8(4):279-87.

PMID:
14518696
6.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group..

N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.

7.

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.

Hardy H, Skolnik PR.

Pharmacotherapy. 2004 Feb;24(2):198-211.

PMID:
14998221
9.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.

J Clin Virol. 2004 Jun;30(2):183-90.

PMID:
15125875
10.

Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.

Belperio PS, Mole LA, Halloran J, Boothroyd DB, Thomas IC, Backus LI.

Ann Pharmacother. 2008 Nov;42(11):1573-80. doi: 10.1345/aph.1L265. Epub 2008 Oct 21.

PMID:
18940919
11.

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Fung HB, Guo Y.

Clin Ther. 2004 Mar;26(3):352-78. Review.

PMID:
15110129
12.

Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.

Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A, Di Perri G.

Infection. 2012 Feb;40(1):69-75. doi: 10.1007/s15010-011-0223-4. Epub 2011 Dec 2.

PMID:
22135137
13.

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.

Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21.

PMID:
16280695
14.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.

AIDS. 2003 Mar 28;17(5):691-8.

PMID:
12646792
15.

Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.

Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J; Alliance Study Group..

Antivir Ther. 2006;11(4):409-19.

PMID:
16856614
16.

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

Clin Ther. 2006 May;28(5):745-54.

PMID:
16861096
17.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.

Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu YY, Zhang Y, McFalls E, Miralles GD, Patel IH.

AIDS. 2006 Feb 14;20(3):397-404.

PMID:
16439873
18.

Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.

True AL, Chiu YY, Demasi RA, Stout R, Patel I.

Pharmacotherapy. 2006 Dec;26(12):1679-86.

PMID:
17125431
19.

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.

Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B.

HIV Clin Trials. 2009 Nov-Dec;10(6):432-8. doi: 10.1310/hct1006-432.

PMID:
20133273
20.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.

AIDS Patient Care STDS. 2007 Aug;21(8):533-43.

PMID:
17711378

Supplemental Content

Support Center